Phase 3RecruitingINTERVENTIONAL
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
ClinicalTrials.gov · NCT06937099 · Registry updated: 2026-10-07
- Condition / research focus
- Crohn's Disease; Obesity or Overweight
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- Austria · Belgium · Brazil · Bulgaria · Canada · Czechia · Denmark · France · Germany · Greece · Hungary · Israel · Italy · Mexico · Netherlands · Poland · Puerto Rico · Romania · Slovakia · Spain · Turkey (Türkiye) · United States
- Registry dates and results
- Start: 2025-06-26. Completion: 2028-05 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Mirikizumab (drug) — also listed as: LY3074828
- Mirikizumab (drug) — also listed as: LY3074828
- Tirzepatide (drug) — also listed as: LY3298176
- Placebo (drug)
Where the study takes place — 183 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.